Asthma News – November 28, 2022
Current asthma research, announcements and opportunities, collected and distributed by Michigan Department of Health & Human Services (MDHHS) Asthma Program Staff.
Sign up to receive weekly-ish news emails.
Check out the most recent
MDHHS asthma social media messages and share them with your networks.
The Environmental Protection Agency invites you to explore data and analysis solutions that can be used to identify where indoor environmental factors may be contributing disproportionately to asthma health burden. Featuring Dr. Andrew Beck of the University of Cincinnati Department of Pediatrics, along with colleagues in pediatrics, population health, local housing and community supports.
The new Environmental Protection Agency webpage provides information about sources of indoor PM (e.g., cooking, combustion and heating sources, indoor dust, mold) and actions you can take to reduce or control them.
This exploratory electronic medical record study demonstrated a significantly greater reduction in asthma exacerbations and systemic corticosteroids prescriptions in patients prescribed with dupilumab versus those on omalizumab, benralizumab, or mepolizumab.
Particulate Matter with a diameter less than 2.5 micrometers (PM2.5) and less than 10 micrometers (PM10) and Nitrogen dioxide (NO2) were significantly and positively associated with sales of R03 (drugs for obstructive airways diseases, overall for asthma) and R06 (antihistamines for systemic use) class drugs, after adjustment for potential confounders.
Risk for IHD was found to be 48% greater in patients with asthma versus non asthmatics. Subgroup analysis revealed significantly increased risk for IHD in patients diagnosed with moderate or severe persistent asthma but not in those with mild persistent asthma.
A new study found that alternating telemedicine with in-person visits for asthma care may result in improved access to care and reduced burdens on patients and families.
Many asthmatics are at risk for exacerbations irrespective of control, adherence, or disease severity. As-needed SABA-ICS should be considered broadly to mitigate variability in airway inflammation that could lead to asthma exacerbations.